Statement re Exclusive Distribution Agreement

    For further information, please contact:

                                                          Medical Solutions plc

                                                                       Nick Ash

                                                              Managing Director

                                                             Tel: [phone]

                                                    www.medical-solutions.co.uk

                                                 Bishopsgate Communications Ltd

                                                         Nick Rome/Gemma O'Hara

                                                             Tel: [phone]

                                              www.bishopsgatecommunications.com

15 February 2008

                             Medical Solutions plc                             

                    ("Medical Solutions" or "the Company")                     

                       EXCLUSIVE DISTRIBUTION AGREEMENT                        

Medical Solutions to distribute the TriPath Imaging, Inc. FocalPoint automated 
                           cytology screening system                           

Medical Solutions plc (LSE: MLS), the provider of expert histopathology
services and liquid based cytology products to the NHS and private healthcare,
is pleased to announce that it has entered into an exclusive agreement with
TriPath Imaging, Inc. to be the UK distributor for the FocalPoint location
guided screening system for automated cytology screening.

This represents an addition to the Company's existing agreement with TriPath
Imaging, Inc. ("TriPath") as the exclusive UK distributor of the SurePath
liquid based cytology ("LBC") system which is widely used for cervical cancer
screening in the UK.

HIGHLIGHTS

  * Exclusive distributor of FocalPoint in the UK;
   
  * The exclusive distribution agreement will form an integral part of the
    Company's strategy to be a leading provider of expert services and products
    to the NHS;
   
  * Medical Solutions continues to adopt new technologies and to enhance its
    portfolio of complementary products and services; and
   
  * Further collaboration with TriPath expected following clinical assessment
    trials as the companies cement their strong relationship.
   
FocalPoint is highly complementary to the existing Medical Solutions cytology
business. This platform enables the automated screening of cytology slides
produced using the SurePath system which Medical Solutions already distributes
and supports.

The UK Pathology Modernisation Program, which is being overseen by Lord Carter,
is high on the Government's agenda and one important aspect of improving
efficiency is automation.

With over 3.5 million cytology slides manually screened for cervical cancer
every year in the UK, and with each screener looking at a maximum of 30 slides
per day, cytology lends itself to automation. The Government is currently
assessing FocalPoint as a primary screening tool as part of a Health Technology
Assessment trial in Manchester. Meanwhile other centres in UK are also
assessing FocalPoint as a quality control technology for cytology.

FocalPoint will extend Medical Solutions' penetration into the cervical
screening market, and enable it to work more closely with laboratories and
Trusts in improving the efficiency of their cervical screening program.

Dr Nick Ash, Managing Director said "The addition of the FocalPoint location
guided screening platform to the existing exclusive distribution agreement
demonstrates the strength of the relationship between Medical Solutions and
both TriPath Imaging, Inc. and its parent company Becton, Dickenson & Company
("BD").

"Whilst completing the LBC roll out programme in the UK, we have been investing
in studies designed to evaluate an automated approach to cervical screening.
Studies conducted within the NHS have already demonstrated that automated
location guided screening can be an effective quality control tool when used in
combination with the existing cervical screening methods. Other studies are
underway to compare its accuracy and cost effectiveness with manual screening."

Dr Ash added "We expect further collaboration with TriPath and BD, and we are
currently undertaking clinical assessment trials on other TriPath and BD
products in the UK, working closely with their research and development team."

                                   - ends -                                    

About Medical Solutions

Medical Solutions plc (LSE: MLS) is a leading provider of expert, quality
services and products to the healthcare, pharma biotech and life science
research sectors. Its Healthcare operations provide screening and reference
laboratory diagnostic testing for cancer and other diseases and additional
predictive testing for treatment optimisation for clinicians and patients.
Pharma Biotech Services offers support for early stage therapeutic development,
offering a "one-stop shop" from tissue pathology, immunohistochemistry,
sophisticated image analysis, biomarker determination and assay development to
pharmacogenomics including genotyping and gene expression analysis. The Life
Science Research services provide core laboratory research support from
conceptualization to implementation, calling upon a wide range of cutting-edge
technology platforms including an online catalogue of biomolecular tools. This
incorporates DNA sequencing, whole genome amplification and a comprehensive
library of genomic reagents and clones including cDNA and RNAi.

The group has its headquarters in Nottingham, UK where it operates state of the
art reference laboratory facilities, with additional UK laboratory facilities
in Cambridge and Oxford. Medical Solutions is CPA and GLP accredited and is
licensed by the Human Tissue Authority.

About Focal Point and location guided screening

Assessment trials are underway or completed in England, Wales and Ireland on
the FocalPoint automated imaging system for use in cervical cancer screening.
The system firstly automatically scans cervical cytology slides and then, using
sophisticated algorithms, the location guided screening platform guides the
cytology screener to areas on a slide where there may be abnormal cells
present, possibly indicating the presence of cervical cancer. The FocalPoint
system identifies ten fields of view where it determines abnormal cells may be
present, to which it then guides the screener. This compares with the 60 fields
of view that a screener would normally review of each slide. Since there is no
loss of accuracy this represents a significant potential benefit to the speed
and efficiency with which cervical cancer screening can be conducted.



END